SCHEMBL21994252

SCHEMBL21994252

C/C(=N\NC(=S)NN)c1ccco1

nearest known ligand 0.72

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.69
GAA P10253 7/20 0.69
TDP1 Q9NUW8 1/20 0.66
POLB P06746 2/20 0.56
RAB9A P51151 7/20 0.52
NPC1 O15118 5/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
PKM P14618 1/20 0.49
KMT2A Q03164 2/20 0.48
MAPT P10636 3/20 0.47
MEN1 O00255 1/20 0.47
MCL1 Q07820 1/20 0.47
CTDSP1 Q9GZU7 1/20 0.47
USP2 O75604 1/20 0.47
LMNA P02545 1/20 0.47
TP53 P04637 1/20 0.47
HPGD P15428 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL942207 0.84 ALDH1A1 (0.64) ALDH1A1GAATDP1POLBRAB9A
SCHEMBL940739 0.84 ALDH1A1 (0.64) ALDH1A1GAATDP1POLBRAB9A
SCHEMBL9656234 0.76 POLB (0.69) ALDH1A1GAATDP1POLBRAB9A
SCHEMBL9656226 0.76 POLB (0.69) ALDH1A1GAATDP1POLBRAB9A
SCHEMBL4259034 0.76 ALDH1A1 (0.64) ALDH1A1GAATDP1POLBRAB9A
SCHEMBL4259031 0.76 ALDH1A1 (0.64) ALDH1A1GAATDP1POLBRAB9A
SCHEMBL12443527 0.76 ALDH1A1 (1.00) ALDH1A1GAATDP1POLBRAB9A
SCHEMBL22056110 0.76 RAB9A (0.60) ALDH1A1GAATDP1POLBRAB9A
SCHEMBL13930637 0.76 ALDH1A1 (0.64) ALDH1A1GAATDP1POLBRAB9A
SCHEMBL29883256 0.76 RAB9A (0.60) ALDH1A1GAATDP1POLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059160-A1 Chemical Activators of Nicotinamide Mononucleotide adenylyltransferase 2 (NMNAT2) and Uses Thereof TSINGHUA UNIVERSITY (CN) 2025-02-20 US claimed
CN-115197126-A Novel NMNAT enzyme agonist and preparation and application thereof 清华大学 2022-10-18 CN claimed
WO-2020107221-A1 CHEMICAL ACTIVATORS OF NICOTINAMIDE MONONUCLEOTIDE ADENLYLY TRANSFERASE 2 (NMNAT2) AND USES THEREOF TSINGHUA UNIVERSITY (CN) 2020-06-04 WO claimed
US-20250059160-A1 Chemical Activators of Nicotinamide Mononucleotide adenylyltransferase 2 (NMNAT2) and Uses Thereof TSINGHUA UNIVERSITY (CN) 2025-02-20 US disclosed
CN-115197126-A Novel NMNAT enzyme agonist and preparation and application thereof 清华大学 2022-10-18 CN disclosed
WO-2020107221-A1 CHEMICAL ACTIVATORS OF NICOTINAMIDE MONONUCLEOTIDE ADENLYLY TRANSFERASE 2 (NMNAT2) AND USES THEREOF TSINGHUA UNIVERSITY (CN) 2020-06-04 WO disclosed
WO-2020107221-A1 CHEMICAL ACTIVATORS OF NICOTINAMIDE MONONUCLEOTIDE ADENLYLY TRANSFERASE 2 (NMNAT2) AND USES THEREOF TSINGHUA UNIVERSITY (CN) 2020-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250059160-A1 Chemical Activators of Nicotinamide Mononucleotide adenylyltransferase 2 (NMNAT2) and Uses Thereof NAMPT, NNMT, NAPRT ALDH1A1 1017/4885GAA 448/4885TDP1 1003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.